Taro Pharmaceutical Industries Ltd. (TARO)
| Market Cap | 2.42B |
| Revenue (ttm) | 578.45M |
| Net Income (ttm) | 29.50M |
| Shares Out | 37.93M |
| EPS (ttm) | 0.77 |
| PE Ratio | 81.06 |
| Forward PE | 15.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 287 |
| Open | 63.77 |
| Previous Close | 63.89 |
| Day's Range | 62.58 - 62.58 |
| 52-Week Range | 56.53 - 80.00 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 80.00 (+27.8%) |
| Est. Earnings Date | Oct 27, 2021 |
About TARO
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, ...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TARO stock is "Buy" and the 12-month stock price forecast is 80.00.
News
Taro to Announce Second Quarter Results on October 28, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE SECOND QUARTER RESULTS ON OCTOBER 28, 2021
Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates
Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Taro Provides Results for Quarter Ended June 30, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2021
Taro to Announce First Quarter Results on July 27, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE FIRST QUARTER RESULTS ON JULY 27, 2021
Taro Pharma (TARO) Sees Hammer Chart Pattern: Time to Buy?
Taro Pharmaceutical Industries (TARO) has been struggling lately, but the selling pressure may be coming to an end soon.
Taro Announces Resignation of Chief Financial Officer
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2021
Taro Provides Results for the Year Ended March 31, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Provides Results for the Year Ended March 31, 2021
Earnings Preview for Taro Pharmaceutical Indus
Taro Pharmaceutical Indus (NYSE:TARO) unveils its next round of earnings this Wednesday, May 19. Here is Benzinga's everything-that-matters guide for the earnings announcement.
Taro to Announce Full Year Results on May 19, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 19, 2021
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2021 Results - Earnings Call Transcript
Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Top Estimates
Taro (TARO) delivered earnings and revenue surprises of 53.25% and 14.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Misses Q1 Earnings and Revenue Estimates
Taro (TARO) delivered earnings and revenue surprises of -34.48% and -25.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks
Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.
Taro Pharmaceuticals: Strong Balance Sheet and Strong Competition
Value investors like companies with strong balance sheets and no debt; it means there are no worries about the company going broke or getting into serious financial trouble.
Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript
Taro Pharmaceutical Industries Ltd.'s (TARO) CEO Uday Baldota on Q4 2020 Results - Earnings Call Transcript
Taro Pharmaceutical (TARO) Misses Q4 Earnings Estimates
Taro (TARO) delivered earnings and revenue surprises of -7.19% and 3.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Former Taro Pharmaceutical VP Of Sales And Marketing Indicted for Price Fixing
Taro Pharmaceutical Industries Ltd (NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tuesday, Reute...
Taro Pharmaceutical (TARO) Surpasses Q3 Earnings Estimates
Taro (TARO) delivered earnings and revenue surprises of 14.29% and -14.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript
Taro Pharmaceutical Industries Ltd. (TARO) CEO Uday Baldota on Q2 2020 Results - Earnings Call Transcript
Taro Pharmaceutical (TARO) Q2 Earnings and Revenues Lag Estimates
Taro (TARO) delivered earnings and revenue surprises of -15.12% and -4.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) to Report Q1 Results: Wall Street Expects Earnings Growth
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Taro Pharmaceutical (TARO) Could Be Positioned for a Slump
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.